Abbott Reallocates Capital Toward High-Margin MedTech and Diagnostics
Abbott is shifting its focus from a declining Nutrition segment to high-margin areas such as MedTech and diagnostics. The company has stabilized margins in the Nutrition business through pricing actions, enabling reinvestment into growth segments like Medical Devices, which reported 8.4% comparable sales growth.
Tickers: $ABT $BSX $ISRG $JNJ $MDT